Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01048593 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety Study of IBI-10090 in Patients Undergoing Cataract Surgery
A Phase 2 study, sponsored by ICON Bioscience.
- Terminated
- Registry status
- Phase 2
- Development phase
- 6
- Enrollment target
NCT01048593 is a Phase 2 study that was terminated before completion, run by ICON Bioscience. The registered enrollment target is 6 participants.
The verdict
NCT01048593, a Phase 2 study, was terminated before completion, sponsored by ICON Bioscience.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 6 participants
- Enrollment target
Study Summary
This study will test the efficacy and safety of IBI-10090 for the reduction of ocular inflammation after cataract surgery.
Interventions
- DRUG IBI-10090
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2010-01 |
| Est. Completion | 2010-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01048593
The ClinicalTrials.gov registry entry for NCT01048593 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ICON Bioscience, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which IBI-10090 is the first listed.
NCT01048593 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01048593 about?
NCT01048593 is a clinical study titled "Efficacy and Safety Study of IBI-10090 in Patients Undergoing Cataract Surgery". This study will test the efficacy and safety of IBI-10090 for the reduction of ocular inflammation after cataract surgery.
What is the current status of trial NCT01048593?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2010-01. Estimated completion is 2010-06.
What interventions are being tested in trial NCT01048593?
The interventions under investigation include: IBI-10090 (DRUG).
Who is sponsoring clinical trial NCT01048593?
This trial is sponsored by ICON Bioscience, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.